Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NVO 
Novo Nordisk A/S (NVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/27/2026: NVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $53.67
1 Year Target Price $53.67
| 4 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 167.22B USD | Price to earnings Ratio 10.34 | 1Y Target Price 53.67 |
Price to earnings Ratio 10.34 | 1Y Target Price 53.67 | ||
Volume (30-day avg) 12 | Beta 0.4 | 52 Weeks Range 37.31 - 89.43 | Updated Date 02/27/2026 |
52 Weeks Range 37.31 - 89.43 | Updated Date 02/27/2026 | ||
Dividends yield (FY) 4.94% | Basic EPS (TTM) 3.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-03 | When After Market | Estimate 5.9 | Actual 6.04 |
Profitability
Profit Margin 33.14% | Operating Margin (TTM) 44.53% |
Management Effectiveness
Return on Assets (TTM) 17.43% | Return on Equity (TTM) 60.7% |
Valuation
Trailing PE 10.34 | Forward PE 13.16 | Enterprise Value 184153304574 | Price to Sales(TTM) 0.54 |
Enterprise Value 184153304574 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 3.77 | Enterprise Value to EBITDA 7.43 | Shares Outstanding 3369988201 | Shares Floating 3188747760 |
Shares Outstanding 3369988201 | Shares Floating 3188747760 | ||
Percent Insiders 0.15 | Percent Institutions 9.49 |
Upturn AI SWOT
Novo Nordisk A/S
Company Overview
History and Background
Novo Nordisk A/S is a global healthcare company founded in 1923 in Denmark. It was formed from the merger of two Danish companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium, both pioneers in insulin production. Key milestones include the development of the first human insulin analogue in the 1980s and the introduction of GLP-1 receptor agonists for diabetes and obesity treatment. The company has evolved into a leading biopharmaceutical firm focused on chronic diseases.
Core Business Areas
- Diabetes Care: Focuses on the discovery, development, manufacturing, and marketing of insulin, insulin delivery systems, and other antidiabetic drugs, including GLP-1 receptor agonists and oral semaglutide.
- Obesity Care: A rapidly growing segment dedicated to developing and marketing treatments for weight management, primarily through GLP-1 receptor agonists.
- Rare Blood and Endocrine Disorders: Provides treatments for hemophilia, growth disorders, and other rare endocrine conditions.
Leadership and Structure
Novo Nordisk is led by a Board of Directors and an Executive Management team. The CEO is Lars Fruergaard Ju00f8rgensen. The company operates with a matrix organizational structure, with global business units and regional operations.
Top Products and Market Share
Key Offerings
- Ozempic: A GLP-1 receptor agonist for type 2 diabetes treatment, administered via injection. It has shown significant efficacy in blood glucose control and cardiovascular risk reduction. Competitors include Eli Lilly and Company (Mounjaro/tirzepatide), AstraZeneca (Bydureon/exenatide). Market share is substantial within the GLP-1 market.
- Wegovy: A higher-dose formulation of semaglutide (the active ingredient in Ozempic) approved for chronic weight management. It represents a significant advancement in obesity treatment. Competitors include Eli Lilly and Company (Zepbound/tirzepatide). It has rapidly captured a significant share of the emerging obesity drug market.
- Insulin Products (e.g., Tresiba, Levemir): A range of modern insulin formulations and delivery systems for diabetes management. These compete with products from Eli Lilly and Company, Sanofi, and others. While a mature market, Novo Nordisk maintains a strong presence.
- Ryzodeg: A combination of degludec and liraglutide for diabetes management. Competes with other fixed-ratio insulins and combination therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in diabetes and obesity care, is characterized by rapid innovation, significant R&D investment, and a growing global patient population suffering from chronic diseases. The rise of GLP-1 receptor agonists has revolutionized treatment approaches. Regulatory scrutiny and pricing pressures are key factors.
Positioning
Novo Nordisk is a dominant player in diabetes care and a leader in the rapidly expanding obesity market, largely due to its successful GLP-1 receptor agonist franchise. Its strong R&D pipeline, established manufacturing capabilities, and global reach are key competitive advantages. The company benefits from a strong brand reputation and deep understanding of chronic disease management.
Total Addressable Market (TAM)
The global diabetes market is valued in the hundreds of billions of dollars, with significant growth expected. The obesity market is also experiencing exponential growth, projected to reach tens of billions of dollars. Novo Nordisk is exceptionally well-positioned to capture a substantial portion of this TAM through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Leading market position in diabetes and obesity care.
- Strong R&D pipeline with innovative therapies.
- Established global manufacturing and distribution network.
- High brand recognition and patient/physician loyalty.
- Significant intellectual property portfolio.
Weaknesses
- High reliance on a few key blockbuster drugs (Ozempic, Wegovy).
- Potential for increased competition as patents expire or new entrants emerge.
- Manufacturing capacity constraints can arise from high demand.
- Pricing scrutiny from governments and payers.
Opportunities
- Expanding the indications for GLP-1 agonists to other chronic diseases (e.g., cardiovascular, kidney disease).
- Growth in emerging markets.
- Leveraging AI and big data for drug discovery and personalized medicine.
- Strategic acquisitions or partnerships to enhance R&D or market access.
- Increased global awareness and demand for obesity treatments.
Threats
- Intensifying competition from other pharmaceutical companies.
- Development of novel therapies by competitors that surpass current offerings.
- Changes in regulatory policies or reimbursement landscapes.
- Patent cliffs and generic competition for existing drugs.
- Supply chain disruptions or manufacturing issues.
Competitors and Market Share
Key Competitors
- Eli Lilly and Company (LLY)
- Sanofi S.A. (SNY)
- AstraZeneca PLC (AZN)
Competitive Landscape
Novo Nordisk holds a leading position due to its pioneering work in GLP-1 agonists. Eli Lilly is a significant and growing competitor with its own highly effective GLP-1/GIP dual agonist. Sanofi is a historical player in insulin but is working to regain momentum in newer diabetes and obesity treatments. AstraZeneca has a presence in diabetes but is less dominant in the GLP-1 and obesity space compared to NVO and LLY.
Major Acquisitions
Catalent
- Year: 2024
- Acquisition Price (USD millions): 16500
- Strategic Rationale: To enhance its manufacturing capacity and secure supply for its blockbuster obesity and diabetes drugs. This acquisition aims to bolster production of semaglutide and other key therapies.
Dicerna Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 3300
- Strategic Rationale: To advance its capabilities in RNA interference (RNAi) therapeutics, expanding its pipeline into new therapeutic areas beyond diabetes and obesity, such as cardiovascular and liver diseases.
Growth Trajectory and Initiatives
Historical Growth: Novo Nordisk has experienced significant historical growth, particularly in the last decade, as it expanded its portfolio and market reach in diabetes and obesity. The introduction of semaglutide-based products has been a major catalyst for recent growth.
Future Projections: Analyst estimates project continued strong growth for Novo Nordisk, driven by the ongoing demand for its obesity and diabetes medications, as well as the expansion of its product pipeline into new therapeutic areas. Growth is expected to remain robust, albeit potentially moderating from the exceptionally high rates seen recently.
Recent Initiatives: Recent strategic initiatives include significant investments in expanding manufacturing capacity to meet demand for semaglutide, accelerating clinical trials for new indications and next-generation therapies, and exploring strategic partnerships in areas like AI-driven drug discovery and gene therapy.
Summary
Novo Nordisk is a highly successful pharmaceutical company with a dominant position in the diabetes and rapidly growing obesity markets, driven by its innovative GLP-1 receptor agonist franchise. Its strong financial performance, robust R&D pipeline, and strategic acquisitions of manufacturing capabilities highlight its current strength. However, it must remain vigilant against increasing competition and potential regulatory challenges, while effectively managing supply chain demands for its blockbuster drugs.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Novo Nordisk Investor Relations
- Company Annual Reports
- Financial News Outlets (e.g., Reuters, Bloomberg)
- Pharmaceutical Industry Market Research Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is illustrative and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novo Nordisk A/S
Exchange NYSE | Headquaters - | ||
IPO Launch date 1982-01-04 | President, CEO & Member of the Management Board Mr. Maziar Mike Doustdar | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 68794 | Website https://www.novonordisk.com |
Full time employees 68794 | Website https://www.novonordisk.com | ||
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.